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ABSTRACT 
The pediatric ocular cancer retinoblastoma is the only central nervous system tumor 
readily observed without specialized equipment: it can be seen by, and in, the naked 
eye. This accessibility enables unique imaging modalities. Here, we review this cancer 
for a neuroscience audience, highlighting these clinical and research imaging options, 
including fundus imaging, optical coherence tomography, ultrasound, and magnetic 
resonance imaging. We also discuss the subtype of retinoblastoma driven by the MYCN 
oncogene more commonly associated with neuroblastoma, and consider trilateral 
retinoblastoma, in which an intracranial tumor arises along with ocular tumors in 
patients with germline RB1 gene mutations. Retinoblastoma research and clinical care 
can offer insights applicable to CNS malignancies, and also benefit from approaches 
developed elsewhere in the CNS. 
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SIGNIFICANCE 
Retinoblastoma is the most common eye cancer in children. It arises in the 
developing retina, part of the central nervous system (CNS). Thus, retinoblastoma is a 
CNS cancer viewable from outside. Retinoblastoma is usually caused by mutations in 
the RB1 gene, but can also be caused by amplification of the neuroblastoma oncogene 
MYCN. Rarely, RB1 gene mutations cause a tumor within the brain as well as eye 
tumors. Retinoblastoma can be imaged by multiple means, including visually through 
the eye, by ultrasound, magnetic resonance, and optical coherence tomography. 
Together, these features make retinoblastoma a unique case study amongst CNS 
tumors. 
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INTRODUCTION 
The pediatric retinal tumor retinoblastoma is the most common eye cancer in 
children. It is unique amongst CNS tumors as it is visible through the eye without 
requiring invasive imaging. This provides an unparalleled opportunity to image tumors 
as they develop or respond to treatment. Moreover, retinoblastoma provides intriguing 
insights into nervous system disease in its trilateral and MYCN-driven forms. 
In this review, we introduce retinoblastoma with a focus on these features. In the first 
part of the review, we describe the clinical, molecular and histological features of this 
tumor in the context of its treatment and prognosis. In the second section of the review, 
we focus on innovations in the imaging of retinoblastoma to highlight what this pediatric 
ocular cancer tells us about CNS malignancy. We follow this with a discussion of the 
aforementioned trilateral and MYCN-driven forms of retinoblastoma, with the goal of 
highlighting what retinoblastoma research can gain from studies of other CNS 
malignancies, and vice versa. 
RETINOBLASTOMA OVERVIEW 
Clinical vignette. A mother in urban Canada is taking photographs of her child, 
when she notices a strange white reflex in the child’s eye (Fig. 1a). Unsure what it is, 
later that night she types “white eye in baby” into an Internet search engine. A list of 
results pops up, alerting her that a white pupil could be a sign of cancer. She 
immediately seeks attention at the nearest hospital, where the child is diagnosed with 
retinoblastoma. 
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 5
Similarly, one evening a mother in rural India notices a white reflex in the eye of her 
child. Her baby does not seem bothered by it, so she does not worry about it too much. 
Later that month a community health worker arrives to check on the family. The mother 
asks about the odd white reflection in her baby’s eye. The health worker has just been 
trained on a new app that helps in the diagnosis of eye conditions. Using her 
smartphone, she takes a flash photo of the child’s eye, and uses the app’s database of 
eye conditions to compare her photograph. She realizes the photo she took looks 
similar to the database photo of retinoblastoma, so she refers the family to hospital. 
Clinical features. These hypothetical cases illustrate typical presentations of 
retinoblastoma. The incidence of retinoblastoma is constant worldwide at 1 in every 
16,000 live births (Dimaras et al. 2015; Dimaras et al. 2012). As such, countries with 
higher birth rates and populations observe the highest number of cases. The most 
common first signs of retinoblastoma are leukocoria, a white reflex visible through the 
pupil (Fig. 1a), and strabismus, misaligned eyes. Awareness of these early signs of eye 
cancer is crucial to good outcomes for affected children. However, where awareness of 
these signs is low, and access to healthcare is challenging, retinoblastoma is often 
diagnosed late. In this case, the most common sign at presentation may be proptosis, 
where tumor causes the eye to bulge from the orbit. Retinoblastoma can affect one or 
both eyes, and sometimes also the pineal, parasellar or suprasellar regions (trilateral 
retinoblastoma, discussed below). 
Detection of retinoblastoma by lay people is possible because retinoblastoma is a 
visible tumor with distinct features. Several awareness efforts aim to improve public 
knowledge of the early visible signs of retinoblastoma. These include low-tech 
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 6
innovations, such as including images of leukocoria in Maternal Child Health booklets 
(Ministry of Health Kenya 2010) provided to mothers shortly after childbirth, to alert 
them of the signs of retinoblastoma. High-tech innovations include concepts like the 
Portable Eye Examination Kit (Peek), a smartphone application that allows users to 
recognize and detect eye conditions, including retinoblastoma (Bastawrous 2016; 
Bastawrous et al. 2015; Lodhia et al. 2016; Morjaria et al. 2017). 
Medical diagnosis of retinoblastoma is based on the clinical features of the tumors 
visible in the eye upon dilation of the pupil (Dimaras et al. 2012) (Fig. 1b). This differs 
from diagnosis of other cancers, where histological confirmation via biopsy is usually 
required. Biopsy of retinoblastoma is not recommended, as it can induce seeding and 
extraocular spread along the needle tract (Karcioglu 2002).  
Retinoblastoma is often highly calcified (Fig. 1c) (Bullock et al. 1977). Calcification is 
visible to the naked eye, and can also be detected by ultrasound or MRI (Rodjan et al. 
2015) (see below). Calcification in retinoblastoma is ‘dystrophic’ (Eagle 2013), that is, it 
occurs in response to tissue damage or necrosis. It is more often observed in tumors of 
older children and advanced retinoblastoma (Levy et al. 2011). 
Retinoma, the benign precursor of retinoblastoma, also displays calcification, along 
with several distinct clinical features; it is described clinically as a grey, translucent 
mass, often with chorioretinal atrophy and variation in the retinal pigment epithelium 
(Dimaras et al. 2009; Dimaras et al. 2008; Gallie et al. 1982b). Retinoma is rare, but can 
be sometimes observed in parents of children with retinoblastoma (Dimaras et al. 2008; 
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 7
Gallie et al. 1982a). Its rare occurrence suggests that most retinomas undergo 
malignant transformation to retinoblastoma. 
Growing retinoblastoma tumors produce seeds that detach and adhere below the 
retina (subretinal seeds) or float into the vitreous (vitreous seeds). The appearance of 
seeds has been described as fine dust, spheres, or clouds, each with a progressively 
worse prognosis, respectively (Francis et al. 2015; Francis et al. 2016; Munier 2014). 
Large tumors can lift and detach the retina, and cause significant inflammation and 
necrosis, sometimes leading to phthisis bulbi (shrinkage of the eye) (Gallie et al. 1982b; 
Kashyap et al. 2011). 
Tumor can spread beyond the eye by surpassing retinal boundaries, such as 
Bruch’s membrane, to invade the choroid and reach the blood supply. Another common 
route for tumor dissemination is via the optic nerve to reach the brain and cerebrospinal 
fluid (CSF) (Mallipatna et al. 2017). 
Staging. The features of retinoblastoma at presentation provide data to accurately 
classify the disease in each eye, and consequently direct treatment. During the era 
when retinoblastoma was primarily treated by radiation, the Reese-Ellsworth 
Classification (Reese and Ellsworth 1963) system was used, separating tumor classes 
by their predicted response to radiation treatment. As systemic chemotherapy began to 
replace radiation as the most common form of treatment, the International Intraocular 
Retinoblastoma Classification (IIRC) (Murphree 2005) system was developed. This 
system is largely based on natural progression of disease from small tumors away from 
the macula (easily treatable with laser therapy) and larger, central tumors with variable 
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degrees of seeding and retinal detachment (requiring chemotherapy in addition to focal 
therapy). Modifications to the original IIRC were later introduced by another group 
(Shields et al. 2006), making it difficult to compare across studies and centers 
(Novetsky et al. 2009). The critical differences between the classification systems have 
previously been reviewed (Dimaras et al. 2015). Other classification schemes include 
staging of extraocular retinoblastoma (Chantada et al. 2006) and staging of vitreous 
seeding (Francis et al. 2015; Francis et al. 2016; Munier 2014).  
As with other cancers, retinoblastoma is also staged using the American Joint 
Commission on Cancer (AJCC)’s “Tumor Node Metastasis” (TNM) classification 
system. The most recent 8th edition of the TNM (Mallipatna et al. 2017) aims to provide 
a way forward for retinoblastoma classification given the above eye-based classification 
confusion. The Tumor stage is first applied per eye based on clinical features, and the 
patient’s score is based on the most advanced eye (Mallipatna et al. 2017). Radiology 
plays an important role in determining the Metastasis stage, particularly in delineating 
any involvement of the CNS.  The 8th edition of the TNM also includes a new feature, 
the additional “H” or heritable trait, which denotes risk of multifocal tumors that can 
affect both eyes and brain (trilateral retinoblastoma). As yet, trilateral retinoblastoma is 
not staged by the TNM system. In fact, no other tumors of the CNS are staged by TNM, 
as tumor size is not a prognostic indicator, the brain and spinal cord do not have a 
lymphatic system, and metastases are rarely distant (Laws Jr. et al. 2017). 
Retinoblastoma is a unique CNS tumor in this respect, as tumor size is prognostic, it 
can affect preauricular, submandibular or cervical nodes, and distant metastases occur 
(Mallipatna et al. 2017). 
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Pathology. Retinoblastoma is a small round blue-cell tumor (Fig. 1d-e), and thus 
bears histologic similarity to other childhood nervous system tumors including 
neuroblastoma and medulloblastoma. Cells are primarily composed of large basophilic 
nuclei and little cytoplasm. The tumor is highly proliferative, displaying abundant 
mitoses and necrosis. Cells may take on a polygonal shape and mimic cobblestones 
when packed together (Tso 1980). Often, collars of viable cells can be observed around 
a blood vessel, surrounded by necrosing cells (Fig. 1f). Tumors display varying degrees 
of differentiation. Cellular differentiation is primarily in the form of Flexner-Wintersteiner 
rosettes and Homer Wright rosettes (Tso 1980) (Fig. 1e). Flexner-Wintersteiner rosettes 
are composed of an ‘empty’ lumen surrounded by columnar cells (Wippold and Perry 
2006). Homer Wright rosettes consist of cells surrounding a central lumen made up of 
their processes (Wippold and Perry 2006). While each type is individually common in 
other neural tumors, the dual presence of Homer Wright and Flexner-Wintersteiner 
rosettes is pathognomonic for retinoblastoma. 
Retinoma histopathology is distinct from retinoblastoma (Fig. 1g). This benign 
precursor is composed of sparsely spaced round cells, and does not contain rosettes. 
Instead, it is characterized by the presence of fleurettes, composed of clusters of cells 
with long, bulbous cytoplasmic processes, mimicking the fleur-de-lys (Dimaras et al. 
2009; Dimaras et al. 2008). Retinoma is observed next to retinoblastoma in 16-20% of 
eyes enucleated for retinoblastoma (Dimaras et al. 2008; Eagle 2009). 
Cellular differentiation has not been conclusively linked to prognosis, and thus does 
not form part of the histological evaluation of tumors. However, the degree of anaplasia 
evident in retinoblastoma has been shown to correlate with prognosis (Mendoza et al. 
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2015), but this has not yet become part of routine histological evaluation. The pathology 
TNM (pTNM) classification determines extent of tumor involvement of the optic nerve, 
choroid, sclera and anterior segment (Finger 2009; Gallie et al. 2016; Mallipatna et al. 
2017).  High risk of metastasis (pT3) is conveyed by >3 mm of tumor in the choroid (the 
vascular layer of the eye, under the retina), tumor extending beyond the lamina cribrosa 
of the optic nerve (the perforated or ‘mesh-like’ structure in the sclera through which the 
fibers of the optic nerve exit the eye), or significant invasion of the sclera. Extraocular 
disease (pT4) is marked by tumor at the cut end of the nerve, involvement of the 
episclera, or invasion of adjacent bone, eyelid, conjunctiva, or muscle (Mallipatna et al. 
2017). 
Genetics. Retinoblastoma is perhaps best known to cancer biologists as the 
inspiration for the “two-hit hypothesis” for oncogenesis, which states that loss of both 
alleles of a tumor suppressor gene are necessary to initiate cancer. Working in the pre-
genomic era, Alfred Knudson noted an earlier age of onset for bilateral retinoblastoma 
than for unilateral (Knudson 1971). His mathematical analysis implied two rate-limiting 
steps were needed for unilateral retinoblastoma to develop, while only a single rate-
limiting step was required for bilateral cases. Fifteen years later, the “retinoblastoma 
gene,” RB1, was cloned, confirming Knudson’s prediction (Friend et al. 1986; Fung et 
al. 1987; Lee et al. 1987). Unilateral patients (usually) have lost both wild-type alleles of 
RB1 in a susceptible retinal cell (two hits), leading to a single, unifocal tumor (Fig. 2). 
Conversely, all bilateral patients have a germline mutation in RB1, thus only require a 
second hit to initiate cancer, which (usually) happens in multiple cells, in both eyes. The 
situation is complicated somewhat by low-penetrance alleles, which can be mutated in 
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the germline without promoting bilateral disease (Lohmann et al. 1994). Because of this, 
approximately 15% of unilateral cases have a heritable mutation. 
The irony is not lost on us that while being a visible tumor, retinoblastoma can rob 
vision from the children it affects. If patients grow up to have children of their own, they 
should learn if they have a heritable mutation that could affect their offspring. For all 
families with heritable retinoblastoma, the “visible feature” of retinoblastoma that allows 
early detection is knowledge of the RB1 mutation. Prenatal genetic detection coupled 
with early term delivery (37-38 weeks’ gestation) of the affected infant allows clinical 
teams to monitor the newborn’s retina for the earliest sign of tumor and treat it 
immediately (Soliman et al. 2016). 
The RB1 gene encodes pRB, a key negative regulatory transcription factor 
governing the G1 to S phase cell cycle transition by blocking the interactions of DNA-
binding E2F and DP transcription factors with DNA (Dick and Rubin 2013). In response 
to mitogen-stimulated cyclin-dependent kinase signaling, normal pRB is 
hyperphosphorylated, releasing it from E2F interactions, allowing these factors to 
activate transcription. pRB also has a growing spectrum of roles in differentiation, 
chromatin remodeling, genome stability, and apoptosis (Dimaras and Corson 2016; 
Velez-Cruz and Johnson 2017).  
Over 1000 mutations in RB1 have been documented in retinoblastoma tumors, 
including missense and nonsense mutations, splicing mutations, frameshifts, micro- and 
macrodeletions, and promoter methylation (Lohmann and Gallie 2004). Despite this, a 
small fraction of unilateral cases lack identified RB1 mutations, so it was long postulated 
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that an alternative mechanism of retinoblastomagenesis might be possible. As part of 
an international team, in 2013 we identified that 1.4% of unilateral retinoblastoma, 
lacking RB1 mutations, instead showed amplification of MYCN (Rushlow et al. 2013) 
(Fig. 2), a transcription factor-encoding gene more frequently associated with the 
pediatric peripheral nervous system tumor, neuroblastoma (Ruiz-Perez et al. 2017). 
This finding raises interesting questions about the parallels between retinoblastoma and 
other neuronal tumors; see below. 
Even in retinoblastoma tumors with a defined RB1 mutation, further mutational 
events are needed for malignancy (Corson and Gallie 2007). Retinal cells homozygous 
for RB1 loss can form the benign tumor, retinoma, but develop other genomic changes 
in the progression to malignancy (Dimaras et al. 2008). The spectrum of changes is 
characterized by relatively few mutated genes, especially compared to common adult 
epithelial cancers. The transcriptional corepressor BCOR (BCL6 corepressor) is the 
most commonly mutated gene in retinoblastoma after RB1 (Zhang et al. 2012). 
However, retinoblastoma displays a distinct pattern of genomic gains and losses, 
notably 1q, 2p, and 6p gain, and 16q loss (Kooi et al. 2016b). Candidate progression 
genes with functional evidence in these regions include MDM4 and KIF14 on 1q, 
encoding the p53 regulator mouse double minute 4 and the oncogenic motor protein 
kinesin family member 14, respectively. MYCN is the most commonly amplified gene on 
2p, while on 6p, the best-studied genes are the DNA-binding proto-oncogene DEK and 
the transcription factor E2F3. Genes commonly lost on 16q include CDH11, encoding 
the adhesion protein cadherin-11, and RBL2, encoding the retinoblastoma family 
member p130 (Kooi et al. 2016b; Theriault et al. 2014). In addition, aberrant methylation 
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is seen in the retinoblastoma genome (Benavente and Dyer 2015), including of the 
oncogenic kinase SYK (spleen tyrosine kinase). As in other cancers, a variety of 
microRNAs are also dysregulated in retinoblastoma (Singh et al. 2016), including the 
miR-17~92 cluster and miR-106b~25 (Conkrite et al. 2011). 
Treatment and prognosis. Treatment of retinoblastoma is complex and varied. 
Eyes containing tumors that display clinical features threatening to extend beyond the 
globe may be surgically removed (enucleation) and histologically assessed to determine 
risk of metastasis. Eye salvage may be attempted on less severely affected eyes 
(Dimaras et al. 2015; National Retinoblastoma Strategy 2009), with focal therapy (laser, 
cryotherapy) (Hamel et al. 2000), brachytherapy (Hernandez et al. 1993), and/or 
chemotherapy. Chemotherapy may be systemic, usually with a cocktail of vincristine, 
etoposide, and carboplatin (Chan et al. 1996; Gallie et al. 1996), intra-arterial (Yousef et 
al. 2016), and/or intravitreal (Munier et al. 2012a; Munier et al. 2012b)). Melphalan is the 
preferred drug for these latter modalities. External beam radiation is another effective 
treatment, however this is not preferred due to its added second cancer risks (Temming 
et al. 2016). Trilateral retinoblastoma treatment and outcomes are discussed in a later 
section. 
Left untreated, retinoblastoma will grow and extend beyond the eye. Commonly, it 
invades the regional lymph nodes, bone, bone marrow, and the central nervous system. 
Extension into the CNS can be detected with radiologic imaging. Prognosis for CNS 
disease is much worse than for bone-marrow, as treatment with systemic chemotherapy 
is impeded by the blood-brain barrier (Mallipatna et al. 2017). Cytologic examination can 
detect tumor dissemination in CSF and bone marrow. Monitoring of CSF disease can be 
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also done molecularly, by looking for tumor-specific (non-germline) RB1 mutations or 
post-RB1 loss genomic gains and losses (Bowles et al. 2007; Dimaras et al. 2010b; 
Racher et al. 2016), or tumor-derived GD2 or CRX mRNA expression (Laurent et al. 
2010; Laurent et al. 2013; Torbidoni et al. 2015). 
Individuals with a constitutional RB1 mutation have an increased risk of developing 
second primary tumors, like osteosarcoma, melanoma, lung or bladder cancer later in 
life (MacCarthy et al. 2013). Surveillance for second primary malignancies is not yet 
supported by strong evidence or broad consensus, though some suggest there may be 
a role for annual screening by whole body MRI (Friedman et al. 2014; Kamihara et al. 
2017). More commonly, retinoblastoma survivors are educated on second primary 
tumor risks and instructed to be vigilant about potential signs of new malignancies 
(Kamihara et al. 2017). 
Guidelines for treatment in high income (National Retinoblastoma Strategy 2009) 
and low-and-middle income countries (Kenyan National Retinoblastoma Strategy Group 
2014) are similar, although they account for differences in availability of resources and 
stage of disease at presentation (i.e., low-and-middle-income countries see more cases 
of extraocular and metastatic disease). Patient outcomes are notably worse in low-and-
middle income countries than in high (Dimaras et al. 2015), and further research is 
needed to address social determinants affecting access to quality care (Dimaras et al. 
2010a). 
IMAGING RETINOBLASTOMA 
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Clinical vignette. An adult survivor of bilateral retinoblastoma is pregnant with her 
first child. She undergoes prenatal genetic testing. Her fetus is found to carry her 
familial RB1 mutation and is therefore at risk of developing retinoblastoma. Shortly after 
birth, the infant’s eyes are visually examined, and the retina appears normal in each 
eye. Monthly examinations are scheduled, during which the ophthalmologist inspects 
each eye with the indirect ophthalmoscope, and an imaging specialist documents the 
fundus with digital images. At the second examination after birth, the ophthalmologist 
still does not see any tumors in the eyes. A clear fundus is documented in each eye 
using a high-resolution fundus camera. Next, the imaging specialist uses Optical 
Coherence Tomography (OCT) to image the eyes. Surprisingly, the OCT reveals a tiny 
lump within the inner nuclear layer of the retina in the left eye. Looking back at the 
fundus images, the ophthalmologist notes a slight haze in the exact spot picked up by 
OCT: it is a tiny tumor, originally missed on examination of the photographic images. 
The tumor is treated with focal therapy, preventing its growth and sparing vision (Based 
on similar cases previously reported; Rootman et al. 2013; Soliman et al. 2016). 
Fundus imaging. Images of the fundus (interior surface of the eye), which become 
part of the medical record, facilitate consultation and collaboration, and precise tracking 
of tumor response or resistance to treatment. This kind of longitudinal, visual 
documentation is unique amongst CNS tumors. Before photographic imaging equipment 
was a standard part of ophthalmic care, retinal drawings (Wilson 1975) were used to 
map retinal topography, lesions, relevant landmarks and treatments applied, as 
observed through the indirect ophthalmoscope (Dvorak and Russell 2011). Retinal 
imaging has changed practice by providing a way to digitally document the eye, but 
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retinal drawings still remain an important part of learning to understand the disease 
trajectory. 
Digital retinal imaging via portable fundus camera has revolutionized clinical 
documentation of retinoblastoma (Fig. 1b, 3a, 3d), allowing comparison of pre- and 
post-treatment images (Romanowska Dixon and Morawski 2017) and facilitating 
consultation between centers (National Retinoblastoma Strategy 2009). The RetCamTM 
(Clarity Medical) captures high-resolution, wide-angle photographs, and with scleral 
depression, allows imaging of the retina up to the ora serrata (the anterior edge of the 
retina) (National Retinoblastoma Strategy 2009). Similarly, the ICON camera (Phoenix 
Technology Group), produces wide-field, high-contrast, high-resolution fundus images.  
Unlike fundus drawings, which depict the entire retina in one image, fundus images 
are partial views of the entire retina and must be stitched together to get a whole-retina 
view. Fluorescein angiography with portable fundus camera imaging is also important to 
document vascularization, especially for follow-up of advanced tumors (Kim et al. 2014). 
Ultrasound. The B-scan (10 MHz) 2D ultrasound is commonly used for ocular 
imaging, and has been a part of the diagnostic toolkit in ophthalmology for decades 
(Giglio and Sherman 1979; Kendall et al. 2015; Mrochuk 1990). It is able to distinguish 
between ocular structures such as lens, choroid, retina and sclera, and image and 
measure aberrations in the eye, such as tumors or retinal detachment. Importantly for 
retinoblastoma, B-scan ultrasound allows visualization of calcification, a key feature of 
these tumors, and thus can help confirm diagnosis (National Retinoblastoma Strategy 
2009; Novotny and Krasny 1990) (Fig. 3b). 
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High frequency B-scan ultrasonography (20-50MHz), also known as ultrasound 
biomicroscopy (UBM), produces images with higher resolution than traditional B-scan 
(Pavlin et al. 1990). It first showed promise in the imaging of anterior segment tumors 
more consistently than B-scan (Pavlin et al. 1992; Reminick et al. 1998). For 
retinoblastoma, UBM has been shown to be essential for determining the proximity of 
the tumor to the anterior portion of eye (Vasquez et al. 2011). These are important 
diagnostic details that assist with accurate classification at presentation.  
Furthermore, like other imaging modalities, ocular ultrasonography also allows 
monitoring of tumor regression as treatment progresses, primarily by comparing the size 
of the tumor at each examination to measurements taken at baseline. Unlike the use of 
intraoperative ultrasound for detection of residual disease in brain tumors (Bohringer et 
al. 2009), ocular ultrasound cannot currently distinguish between active and inactive 
retinoblastoma tumor.  
Magnetic Resonance Imaging (MRI). As with other CNS tumors, MRI can provide 
important diagnostic and prognostic information in retinoblastoma (Fig. 3c) and is vital 
for screening for trilateral retinoblastoma (see below). MRI can also aid in characterizing 
the tumor in cases where it is not visible, for instance if it is behind a cataract-containing 
lens.  
Where available, MRI is often used as part of the workup of all patients with 
retinoblastoma, as it can provide vital information about high-risk pathological features 
prior to enucleation (de Graaf et al. 2012). These include: optic nerve invasion 
evidenced by thickening; massive choroidal invasion evidenced by thickening or 
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irregularities, scleral invasion evidenced by signal-enhancing tissue beyond the choroid, 
and intracranial invasion into the suprasellar region (Razek and Elkhamary 2011). 
However, sensitivity for detecting these high-risk features varies considerably (de Jong 
et al. 2014a). High field-strength MRI can also confirm retinoblastoma diagnosis by 
corroborating the calcifications observed by ultrasound or fundus imaging (Galluzzi et 
al. 2009), and can detect vitreous seeds or anterior segment involvement (Razek and 
Elkhamary 2011). Again, these uses are particularly valuable when fundus imaging is 
not possible. Note that computerized tomography (CT) imaging is generally avoided in 
retinoblastoma due to the radiation risks, especially in patients with a germline RB1 
mutation, already at increased risk for second primary tumors. 
In intracranial tumors like gliomas, intraoperative MRI has assumed a pivotal role, to 
detect removal of diseased tissue during surgery (Hlavac et al. 2017). Intraoperative 
MRI is not necessary in retinoblastoma, as enucleation usually removes the entirety of 
the tumor, unless extraocular spread has been previously detected, or high risk features 
are subsequently discovered on pathology. However, one retinoblastoma case report 
describes the use of intraoperative MRI to track the delivery and tumor penetration of 
intra-arterial melphalan delivered in a cocktail with gadolinium (Materin et al. 2012).  
Optical coherence tomography (OCT). OCT, a non-invasive imaging technique 
based on differential near-infrared light reflection, offers a powerful tool for imaging 
retinoblastoma, with resolution exceeding that of ultrasound or MRI. Conceptually 
similar to ultrasound, spectral domain (SD) OCT can generate high resolution, cross-
sectional images of tissues where light can penetrate (Fujimoto and Swanson 2016), so 
has found utility in dermatology, urology, and in particular, ophthalmology, where it is 
Page 20 of 104
Journal of Neuroscience Research
Journal of Neuroscience Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 19 
routinely used in adult clinics. It has also been used in the CNS: for ex vivo analysis of 
gliomas (Valdes et al. 2016) and medulloblastoma (Vuong et al. 2015), and is being 
trialed for intraoperative imaging of gliomas to detect residual tumor, as is also done via 
ultrasound and MRI (Bohringer et al. 2009). 
Recently, with the advent of hand-held intraoperative OCT systems, OCT has 
become popular for pediatric ophthalmology as well, including retinoblastoma 
assessment (Do et al. 2017). Initial publications were case reports indicating the value 
of OCT for detecting cavitary retinoblastoma (Mashayekhi et al. 2005) and reasons for 
visual loss (such as retinal detachment) post-therapy (Shields et al. 2005). 
Subsequently, OCT showed utility for documenting response to therapy, spotting edge 
recurrence, and notably, detecting “invisible” tiny retinoblastoma (Fig. 3d-f) (Rootman et 
al. 2013), as well as assessing foveal anatomy, which impacts the likelihood of visual 
function post-therapy (Cao et al. 2014; Samara et al. 2015). One case report even 
documented optic nerve head disease, usually detected by MRI (see above) (Yousef et 
al. 2012). OCT’s ability to look “behind” small features such as vitreous seeds to the 
underlying tumor or normal retina can be valuable for assessing retinoblastoma 
comprehensively. 
This growing body of work also contributed to an ongoing debate on the cell of origin 
of retinoblastoma, as some tiny tumors detected by OCT seem to originate in the inner 
nuclear layer (Rootman et al. 2013) (Fig. 3f), while others are more localized to the 
outer nuclear layer, suggestive of a cone precursor origin for at least some 
retinoblastoma (Berry et al. 2016), which is consistent with experimental data (Xu et al. 
2014).  
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Although not yet in use for retinoblastoma, recently-developed OCT angiography 
holds considerable promise for documenting vascularization and blood flow in and 
around tumors (Gao et al. 2016). However, OCT does have limitations: it images the 
periphery of the retina poorly (although technology for widefield OCT is improving), and 
relies on transparent media: large tumors and/or cataracts limit its usefulness. Despite 
this, OCT for retinoblastoma is usually successful and can guide treatment decisions 
(Soliman et al. 2017b). With time, OCT will doubtless assume a greater role in the 
staging and management of retinoblastoma, taking true advantage of the accessibility of 
the eye to manage this cancer. 
Imaging animal models. The wealth of imaging tools available for the eye has 
made longitudinal studies of retinoblastoma animal models possible, complementing 
more traditional histological analyses (Fig. 3g). The advent of small animal intraocular 
imagers enabled documentation of intraocular tumors in both transgenic and orthotopic 
xenograft models of the cancer. In particular, coupling fluorescence and brightfield 
imaging of GFP-expressing xenografts allowed qualitative assessment of tumor growth 
and (importantly) dissemination within the eye (Corson et al. 2014). Similarly, a number 
of preclinical therapeutic studies have included qualitative fundus and fluorescein 
angiography images (Brennan et al. 2011; McEvoy et al. 2011; Zhang et al. 2012). In 
the future, quantification of fluorescence should allow volumetric analysis of tumor 
growth, as is currently done using bioluminescence of luciferase-expressing xenografts 
(Corson et al. 2014; Ji et al. 2009; Laurie et al. 2005).  
MRI has also been employed in preclinical treatment trials, and in one report was 
used for volumetric estimation of tumor (McEvoy et al. 2011). Ultrasound has also been 
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used for animal models in limited cases (Brennan et al. 2011); one study showed 
fundus, ultrasound and MRI images of transgenic animals in a treatment trial, but did 
not use these images for assessing efficacy (Nemeth et al. 2011).  
OCT has become a favored method for detecting lesions, especially in genetic 
models. The first work in this area was done with custom-built OCT apparatus, enabling 
detection of intraretinal tumors in the SV40 T-antigen driven mouse model of 
retinoblastoma (TAg-RB) (Ruggeri et al. 2007), and assessing their response to therapy 
(Cebulla et al. 2008). Even retinal tumors in utero could be detected through the uterine 
horn (Larina et al. 2012). TAg-RB tumors have also been documented by ultrasound 
(Foster and Brown 2012). 
More recently, using a commercially-available small animal OCT system, we showed 
that this technique can detect the earliest signs of tumors in the TAg-RB model, 
corresponding to their first appearance by histology (Fig. 3g) (Wenzel et al. 2015), and 
we used this finding to show that overexpression of the oncogene Kif14 accelerates not 
just tumor growth, but tumor initiation in this model as well (O’Hare et al. 2016).  
OCT has proven useful for xenografts: intravitreal xenografts could be monitored 
(Corson et al. 2014; Tschulakow et al. 2016) and subretinal xenografts could be rapidly 
assessed by a combination of OCT and funduscopy (Lemaitre et al. 2017). Of course, 
OCT assessment of morphology of xenografts is less clinically relevant than the 
morphology of tumors arising intraretinally as in genetic retinoblastoma models. 
However, the prospects for rapidly assessing genetic modifiers and/or therapeutic 
efficacy by OCT in both types of model are appealing, especially with the advent of 
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methods to volumetrically assess lesions on OCT (Ruggeri et al. 2009; Sulaiman et al. 
2015). 
MYCN-AMPLIFIED RETINOBLASTOMA 
Clinical vignette. A 1-month-old infant with no family history of retinoblastoma has a 
large retinoblastoma identified in one eye. On enucleation, no rosettes are noted, but 
the high-risk pathological feature of optic nerve invasion is present. Since early-onset, 
aggressive tumors are often indicative of a germline RB1 mutation, heritable disease is 
suspected, with the concomitant risk of tumors in the fellow eye and a need for lifelong 
surveillance and risk to offspring. But genetic analysis of the enucleated tumor fails to 
find any mutated RB1 alleles, despite >96% detection rate in specialized labs (Soliman 
et al. 2017a). However, further analysis of common copy number changes in 
retinoblastoma reveals that the oncogene MYCN is amplified to 53 copies in this tumor, 
and on subsequent re-review, the pathologist notices some neuroblastoma-like 
histological features. These findings strongly suggest MYCN-driven disease, which is 
not heritable, leaving this child at only population risk for future malignancies. 
Discovery and characteristics. MYCN retinoblastoma was identified based on 
careful analysis of over 1000 tumor genotypes (Rushlow et al. 2013). Although MYCN 
amplification had been documented in occasional retinoblastoma since the MYCN gene 
was first identified (Gilbert et al. 1981), this large-scale study was needed to reveal that 
MYCN amplification is much more common amongst unilateral retinoblastoma without a 
detectable RB1 mutation. This finding has since been replicated in other cohorts 
(Ewens et al. 2017; Kooi et al. 2016a; McEvoy et al. 2014), but it is important to note 
that MYCN retinoblastoma is currently only identifiable after enucleation. Retrospective 
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analysis of MYCN retinoblastoma revealed several further differentiating features (Fig. 
4). Clinically, these tumors are amongst the very earliest-onset unilateral tumors, and 
often had high-risk pathological features, although there is not yet sufficient evidence to 
conclude that MYCN amplification has a dramatic effect on aggressiveness, as it does 
in neuroblastoma or medulloblastoma (Ruiz-Perez et al. 2017). Histopathologically, 
these tumors also differ from RB1-/- retinoblastoma. Comparatively, they show more 
rounded, undifferentiated cells, with prominent nucleoli (Fig. 4c), and lack the nuclear 
molding, differentiated rosettes, and extensive calcification commonly seen in 
retinoblastoma. Again, the histology of MYCN retinoblastoma is more similar to 
neuroblastoma than it is to RB1-/- retinoblastoma. 
Molecular features. Beyond the lack of RB1 mutations, MYCN retinoblastoma had 
fewer copy number alterations than RB1-/- tumors in one study (Rushlow et al. 2013), 
although this was not seen in a subsequent report (Ewens et al. 2017). MYCN 
retinoblastoma were also less likely to display the characteristic chromosomal gains and 
losses of retinoblastoma (1q and 6p gain, 16q loss), instead showing some variations in 
common with neuroblastoma (17q gain, 11q loss) (Rushlow et al. 2013). 
MYCN retinoblastomas have functional, hyperphosphorylated pRB (Ewens et al. 
2017), and high levels of N-Myc protein (Rushlow et al. 2013). The fact that pRB is 
expressed, yet inactivated by post-translational modification, strongly implies that 
genetic changes at the RB1 locus are not driving this disease. The SKP2-p27 axis 
leading to pRB phosphorylation was not activated in 3 of 4 MYCN retinoblastoma 
(Ewens et al. 2017), suggesting that this MYCN-activated pathway is not a key driver in 
MYCN retinoblastoma, unlike in neuroblastoma (Evans et al. 2015).  
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Interestingly, high retinal Mycn levels alone (driven by the Pax6α enhancer) could 
not initiate retinoblastoma-like tumors in mice, but could cooperate with Rb1 loss to form 
tumors (which normally require loss of another retinoblastoma family member such as 
p107) (Wu et al. 2017). This discovery also offered a caution toward MYCN-targeted 
therapy: when Mycn levels were reduced in this mouse model, tumors reoccurred with 
Mycn-independence (Wu et al. 2017). Further insight into how MYCN amplification 
leads to pRB inactivation by hyperphosphorylation and drives the human tumors is 
needed. Perhaps the Pax6α enhancer does not drive expression in the retinal cell type 
susceptible to Mycn-driven retinoblastoma; Mycn overexpression alone can promote 
cancer in other tissues, as observed with the tyrosine hydroxylase-driven Mycn 
neuroblastoma model (Weiss et al. 1997). In the absence of perfect mouse models, cell 
lines and patient-derived xenografts will be best suited for these experiments, but given 
the rarity of MYCN retinoblastoma, few are currently available. 
Are MYCN-amplified ocular tumors retinoblastoma? Despite the 
histopathological and genetic similarities with neuroblastoma, there is no reason to 
believe that “MYCN retinoblastoma” is not retinoblastoma: it apparently arises in a 
retinal neuronal precursor, and (based on a small number of tumors) has a gene 
expression profile not statistically distinct from that of a major group of retinoblastoma, 
characterized by low “photoreceptorness”, but high expression of RNA biogenesis and 
M phase genes (Kooi et al. 2015). Thus, to date it is unclear if MYCN retinoblastoma 
derives from a different retinal cell of origin than RB1-/- retinoblastoma, or if the cell of 
origin is the same, but the initiating MYCN amplification event pushes these cells into a 
distinct phenotype. 
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TRILATERAL RETINOBLASTOMA 
Clinical vignette. A 6-month old presents with a 2-week history of leukocoria in one 
eye. Upon ophthalmic examination, the child is diagnosed with unilateral 
retinoblastoma. As part of routine work-up, the child undergoes CT of head and both 
orbits. The CT reveals an intracranial midline tumor. Cytologic examination of the CSF 
shows presence of malignant cells. The child undergoes treatment for trilateral 
retinoblastoma, which includes high-dose chemotherapy followed by autologous stem 
cell transplant. The child is alive and well 10 years post-treatment. (Based on a 
previously reported case; Dimaras et al. 2015; Dimaras et al. 2011). 
A 4-month old presents to the emergency room with atypical eye movements and 
overgrowth syndrome. A CT scan rev als a suprasellar tumor (Fig. 5). The eyes are not 
examined at this time. The tumor is biopsied and shows a small blue cell tumor with 
abundant Flexner-Wintersteiner rosettes. The eyes are then examined, and reveal 
multifocal tumors in both eyes. Systemic and intrathecal chemotherapy for trilateral 
retinoblastoma is prescribed. During the placement of the intrathecal catheter, the 
treating physicians observe tumor seeding along the needle tract of the initial biopsy. 
The child’s tumor reoccurs and she dies. (Based on a previously reported case; (Dai et 
al. 2008; Dimaras et al. 2011). 
Origins and Pathology. Trilateral retinoblastoma, first described in 1977 (Jakobiec 
et al. 1977) and coined in 1980 (Bader et al. 1980), is the heritable form of 
retinoblastoma associated with an intracranial tumor. The intracranial tumors most 
commonly affect the pineal gland, as well as the suprasellar or intrasellar region of the 
brain (Fig. 5). Pineal tumors are generally smaller than non-pineal tumors in trilateral 
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retinoblastoma (de Jong et al. 2014b). Benign pineal cysts have also been observed 
with retinoblastoma (Beck Popovic et al. 2006; Gupta et al. 2016; Karatza et al. 2006). 
In rare cases pineal cysts can transform into malignant tumors, suggesting they should 
be monitored over time (de Jong et al. 2016). Cystic normal pineal glands, however, are 
also regularly observed in children; their size is often comparable to solid and cystic 
pineoblastoma (Sirin et al. 2016). This makes it challenging to know which cystic lesions 
require follow-up, and which do not. A classification for pineal glands has been 
proposed to differentiate glands based on absence or presence of cysts, number of 
cysts, and enlargement (Type 0-4) (Sirin et al. 2016). The European Retinoblastoma 
Imaging Collaboration proposed guidelines for follow-up of cystic pineal lesions based 
on this classification: they recommend monitoring Type 3 and 4 lesions (multicystic with 
enlargement) by routine MRI for changes in size or morphology of the solid component 
of the lesion (Sirin et al. 2016). It is sometimes equally challenging to differentiate large 
solid pineal glands from pineoblastoma (Galluzzi et al. 2016).  
Trilateral retinoblastoma often presents with leptomeningeal metastasis or CSF 
involvement, which is difficult to cure. The histological features of the intracranial tumor 
are identical to those of retinoblastoma (Fig. 5c). Because of its rarity, little work on the 
molecular genetics of this tumor has been reported (Li et al. 2005). Mouse models may 
yet offer some insights: 15%-27% of TAg-RB mice develop primitive neuroectodermal 
tumors, analogous to the parasellar and suprasellar tumors arising in patients with 
trilateral retinoblastoma (Marcus et al. 1991; O’Brien et al. 1990). The trilateral tumors in 
mice have histological features consistent with their human counterparts (Marcus et al. 
1991). However, this murine retinoblastoma model does not develop pineoblastoma 
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(Marcus et al. 1991), although other T-antigen-driven tumor models do (Marcus et al. 
1996). Also, Rb1+/- mice with loss of p53 develop pineoblastomas, but these mice do not 
develop retinal tumors (Williams et al. 1994). Despite the existence of these models, no 
preclinical studies on trilateral retinoblastoma have yet been reported. 
In addition to predisposition by RB1 mutation, pineoblastoma alone is associated 
with germline mutations in DICER1 (de Kock et al. 2014). In murine retinoblastoma 
models, Dicer1 is a haploinsufficient tumor suppressor (Lambertz et al. 2010). Further 
investigation is warranted into the development of pineoblastoma within and without the 
context of retinoblastoma. 
Epidemiology. The incidence of trilateral retinoblastoma among patients with 
heritable retinoblastoma is 3.5% (de Jong et al. 2015). Prior systemic chemotherapy to 
treat retinoblastoma is associated with decreased risk of developing an intracranial 
tumor (Shields et al. 2001). Suprasellar or intrasellar tumors are diagnosed earlier than 
pineal, and often concurrently with the retinoblastoma (Kivela 1999). In contrast, 60% of 
pineal tumors are diagnosed within 1 year of initial retinoblastoma diagnosis, suggesting 
that routine screening by MRI could contribute to earlier diagnosis (de Jong et al. 
2014b). Some centers screen by MRI every 6 months until 5 years of age (Kamihara et 
al. 2017), however it is unclear if this approach is warranted or effective (De Ioris et al. 
2014). 
Becoming treatable. Treatment for trilateral retinoblastoma generally involves 
chemotherapy delivered systemically and intrathecally via an Ommaya reservoir, 
followed by high-dose chemotherapy and autologous stem cell rescue (Dimaras et al. 
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2011). Surgical treatment has been attempted in some cases; however, complete 
resection is difficult due to the locations of the intracranial tumors (Dunkel et al. 2010). 
Craniospinal radiation, while effective, is not preferred because of its long-term 
developmental, neurocognitive and endocrine damage (Duffner et al. 1985; Mulhern et 
al. 1999). Indeed, the use of radiation in the treatment of trilateral retinoblastoma has 
declined in recent years (de Jong et al. 2014b).  
Survival from trilateral retinoblastoma has improved over time, most notably with the 
introduction of high-dose chemotherapy and autologous stem cell transplant (de Jong et 
al. 2014b). Looking at outcomes before and after 1995, when chemotherapy changed 
treatment for retinoblastoma, the 5-year survival for pineal trilateral retinoblastoma has 
increased from 6% to 44%, and non-pineal from 0 to 57% (de Jong et al. 2014b; Kivela 
1999). The presence of leptomeningeal metastases considerably reduces probability of 
survival (de Jong et al. 2014b). 
CONCLUSIONS AND OUTLOOK 
Although rarer than many other CNS cancers, retinoblastoma has offered 
fundamental cancer knowledge, and clinicians and researchers have taken advantage 
of its accessibility to carefully document and treat it using multiple modalities. We 
envisage several areas for future developments to improve our understanding and 
clinical management of this cancer. 
Trilateral retinoblastoma. Our improving knowledge of the clinical behavior of 
intracranial tumors in retinoblastoma has not been matched by our understanding of 
their molecular features. It will be valuable to determine if there are molecular 
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characteristics of certain heritable retinoblastomas that might predispose to formation of 
trilateral tumors. These might include RB1 genotype, DICER1 genotype, protein marker 
expression, features on high resolution imaging, or others. Trilateral retinoblastoma 
tumors (like their anatomical counterparts not associated with retinoblastoma) might 
benefit from targeted therapy, and each could benefit from discoveries in the other in 
this domain. The availability of mice that develop trilateral retinoblastoma-like tumors 
makes preclinical studies technically feasible, but the low frequency of intracranial tumor 
formation in these mice plus the need for histological diagnosis makes such studies 
challenging. 
MYCN retinoblastoma. The study of MYCN retinoblastoma can gain much from the 
wealth of knowledge available for MYCN neuroblastoma (Huang and Weiss 2013). 
Despite caveats (Wu et al. 2017), the potential for targeted agents borrowed from 
neuroblastoma research to treat MYCN retinoblastoma is exciting. Currently, these 
would only be useful for metastatic disease as the MYCN genotype is only determined 
post-enucleation (recall that intraocular retinoblastoma is not biopsied due to risk of 
tumor dissemination). But a promising new ‘liquid biopsy’ technique could change this, 
as it allows for capture and molecular analysis of tumor DNA from the aqueous humor 
of the eye, which can be safely removed with techniques that minimize risk of tumor 
spread (Berry et al. 2017). This approach could potentially be used to identify MYCN 
tumors in situ. Moreover, if distinguishing characteristics of MYCN tumors could be 
discovered in OCT, fundus, ultrasound, or magnetic resonance imaging, or in circulating 
tumor cells or DNA, targeting the primary tumor would also be possible. Large, 
prospective studies will be needed to find these characteristics. Similarly, comparison of 
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the molecular features (genomic, proteomic, and signaling changes) of MYCN 
retinoblastoma with MYCN neuroblastoma may reveal shared vulnerabilities or unique 
characteristics. 
Deciphering the cell of origin of MYCN retinoblastoma is likewise important. One 
way to explore this would be to parallel the work that identified cone precursors as a 
likely origin of at least some RB1-/- retinoblastoma by knocking down RB1 in dissociated 
human fetal retinal cells and observing which cell types can proliferate (Xu et al. 2014). 
A similar experiment, overexpressing MYCN instead of removing RB1, could perhaps 
provide insight into retinal cells susceptible to proliferation after MYCN gain. 
Imaging. Tumor imaging has revolutionized care of retinoblastoma, and could 
perhaps be further applied to research on other CNS tumors. The powerful combination 
of fundus imaging and OCT makes the prospect of xenografting other tumor types into 
the eye an appealing one, especially for neural tumors where intravitreal or subretinal 
injection would be more facile than intracranial xenografting. Although the intraocular 
microenvironment differs from the brain, it offers similarities (neuronal and glial 
neighboring cells, separation from the blood by a semi-permeable barrier) that 
subcutaneous xenografts lack. Such paratopic xenografts could be easily followed using 
the imaging modalities above, and will be an interesting area for further exploration. 
Retinoblastoma may also learn from imaging in CNS tumors. Molecular imaging via 
positron emission tomography (PET) or single photon emission computed tomography 
(SPECT) is showing promise for brain tumors, especially using radiolabeled amino acid 
tracers (Brindle et al. 2017). But the rare research on these imaging modalities in 
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retinoblastoma has shown little-to-no promise, offering no additional insight on tumor 
features or response to treatment (Moll et al. 2004). Further research including novel 
tracer development may be indicated. However, the need to keep radiation exposure 
low for heritable retinoblastoma cases must also be considered. 
Large imaging studies might also reveal other imaging biomarkers that could help 
stratify retinoblastomas for improved prognostication and treatment decisions. Such 
work could impact identification of both trilateral-predisposed and MYCN 
retinoblastoma, as noted above. Further ability to look out for distinctive features in the 
eyes of retinoblastoma patients will continue to improve the outlook for this visible CNS 
tumor. 
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FIGURE LEGENDS 
Fig. 1. Clinical features of retinoblastoma. (a) External RetcamTM image of 
retinoblastoma; calcified tumor is visible through the pupil as leukocoria. (b) RetcamTM 
fundus image revealing two tumors (arrowheads), * = optic nerve head. (c) Gross 
pathology of an enucleated eye. A large, calcified tumor is apparent on the left side of 
the globe (arrowhead). (d) Pupillary-optic nerve section of an eye enucleated for 
retinoblastoma as primary treatment. (e) Homer Wright rosettes (arrowhead) and 
packed cells; (f) Viable collars of cells around blood vessels, and abundant necroses 
between them; (g) Area of retinoma, with fleurettes (arrowhead). Scale bars = 100 µm. 
Fig. 2. Retinoblastoma genetics. The cancer can initiate with a germline RB1 
mutation followed by a single somatic hit, or with two somatic mutations (M1 and M2). 
Loss of RB1 leads to the benign retinoma; further mutations (M3 to Mn) are required for 
malignancy. Retinoblastoma can also initiate by amplification of MYCN, with other 
genomic changes as yet unknown. 
Fig. 3. Retinoblastoma imaging. (a-b) RetcamTM (a) image of an eye reveals two 
large tumors, and ultrasound image (b) allows measurement of tumor height (yellow and 
green lines). (c) Axial T1 MRI post-gadolinium reveals tumor at back of eye 
(arrowhead). (d-f) Imaging of the eye of an infant with heritable retinoblastoma by 
RetcamTM (d) shows no visible tumor. OCT scan line shown in green/red. OCT imaging 
(e, en face; f, transverse section) reveals small tumor appearing to arise out of the inner 
nuclear layer of the retina (arrowhead). (g) Fundus photo (top) and OCT image (bottom) 
show a retinoblastoma-like tumor (arrowheads) arising in the TAg-RB mouse model. 
OCT scan line shown in red. Scale bars = 100 µm. 
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Fig. 4. MYCN retinoblastoma. (a) Tumor appears retinoblastoma-like on fundus 
image. (b) Ultrasound reveals characteristic calcification. (c) Histopathology of tumor in 
enucleated eye reveals round nuclei with prominent large multiple nucleoli; contrast with 
RB1-/- retinoblastoma in Fig. 1e. Adapted with permission from (Rushlow et al. 2013). 
Fig. 5. Trilateral retinoblastoma. (a) Sagittal T1-weighted and (b) coronal T2-
weighted fluid-attenuated inversion recovery (FLAIR) contrast MRI reveals suprasellar 
mass in a patient who also has bilateral retinoblastoma. (c) Histology of this mass 
reveals abundant Flexner-Wintersteiner and Homer Wright rosettes. Scale bar = 25 µm. 
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Fig. 1. Clinical features of retinoblastoma. (a) External RetcamTM image of retinoblastoma; calcified tumor is 
visible through the pupil as leukocoria. (b) RetcamTM fundus image revealing two tumors (arrowheads), * = 
optic nerve head. (c) Gross pathology of an enucleated eye. A large, calcified tumor is apparent on the left 
side of the globe (arrowhead). (d) Pupillary-optic nerve section of an eye enucleated for retinoblastoma as 
primary treatment. (e) Homer Wright rosettes (arrowhead) and packed cells; (f) Viable collars of cells 
around blood vessels, and abundant necroses between them; (g) Area of retinoma, with fleurettes 
(arrowhead). Scale bars = 100 µm.  
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Fig. 2. Retinoblastoma genetics. The cancer can initiate with a germline RB1 mutation followed by a single 
somatic hit, or with two somatic mutations (M1 and M2). Loss of RB1 leads to the benign retinoma; further 
mutations (M3 to Mn) are required for malignancy. Retinoblastoma can also initiate by amplification of 
MYCN, with other genomic changes as yet unknown.  
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Fig. 3. Retinoblastoma imaging. (a-b) RetcamTM (a) image of an eye reveals two large tumors, and 
ultrasound image (b) allows measurement of tumor height (yellow and green lines). (c) Axial T1 MRI post-
gadolinium reveals tumor at back of eye (arrowhead). (d-f) Imaging of the eye of an infant with heritable 
retinoblastoma by RetcamTM (d) shows no visible tumor. OCT scan line shown in green/red. OCT imaging 
(e, en face; f, transverse section) reveals small tumor appearing to arise out of the inner nuclear layer of 
the retina (arrowhead). (g) Fundus photo (top) and OCT image (bottom) show a retinoblastoma-like tumor 
(arrowheads) arising in the TAg-RB mouse model. OCT scan line shown in red. Scale bars = 100 µm.  
 
171x82mm (300 x 300 DPI)  
 
 
Page 52 of 104
Journal of Neuroscience Research
Journal of Neuroscience Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 4. MYCN retinoblastoma. (a) Tumor appears retinoblastoma-like on fundus image. (b) Ultrasound 
reveals characteristic calcification. (c) Histopathology of tumor in enucleated eye reveals round nuclei with 
prominent large multiple nucleoli; contrast with RB1-/- retinoblastoma in Fig. 1e. Adapted with permission 
from Rushlow et al. 2013.  
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Fig. 5. Trilateral retinoblastoma. (a) Sagittal T1-weighted and (b) coronal T2-weighted fluid-attenuated 
inversion recovery (FLAIR) contrast MRI reveals suprasellar mass in a patient who also has bilateral 
retinoblastoma. (c) Histology of this mass reveals abundant Flexner-Wintersteiner rosettes. Scale bar = 25 
µm.  
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Retinoblastoma is a uniquely accessible CNS tumor. Imaging techniques for this cancer, the biology of its 
MYCN-driven form, and its “trilateral,” intracranial manif station provide interesting contrasts and parallels 
with other CNS malignancies.  
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Retinoblastoma is a uniquely accessible CNS tumor. Imaging techniques for this 
cancer, the biology of its MYCN-driven form, and its “trilateral,” intracranial 
manifestation provide interesting contrasts and parallels with other CNS malignancies. 
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